NIKKEI 225
26,911.20 +251.45 (+0.94%) HANG SENG
20,644.28 +41.76 (+0.20%) CRUDE OIL
109.76 -2.64 (-2.35%) GOLD FUTURES
1,814.00 -4.90 (-0.27%) DOW
31,621.74 -1,032.85 (-3.16%) BTC-GBP
23,565.37 -943.26 (-3.85%)
Pharmagest Interactive SA (0R9T.L)
| Previous close | 79.10 |
| Open | 79.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 78.95 - 79.30 |
| 52-week range | 78.95 - 79.30 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 1.158B |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | 34.65 |
| EPS (TTM) | 2.28 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
EQUASENS (Pharmagest Interactive): Q1 2022 revenue: +9.03% to €49.36m
Villers-lès-Nancy, 12 May 2022 - 6:00 p.m. (CET) PRESS RELEASE Q1 2022 revenue: +9.03% to €49.36m Name change completed: Pharmagest Group becomes Equasens Group The Extraordinary General Meeting of 6 May 2022 adopted the resolution changing Pharmagest Group’s name to Equasens Group. Group's Q1 2022 revenue up 9.03% to €49.36m (+7% to €48.44m like-for-like).The Group confirms its positive momentum and growth targets for 2022. In €mQ1 2021Q1 2022 *ChangeRevenue45.2749.36+ 9.03 % * unaudited **** O
- Globe Newswire
Pharmagest Interactive: RESULTS OF THE VOTE ON THE RESOLUTIONS SUBMITTED TO THE EXTRAORDINARY GENERAL MEETING OF 6 MAY 2022
Villers-lès-Nancy, 10 May 2022 - 7:00 a.m. (CET) PRESS RELEASE RESULTS OF THE VOTE ON THE RESOLUTIONS SUBMITTED TO THE EXTRAORDINARY GENERAL MEETING OF 6 MAY 2022 Number of shares comprising the share capital: 15,174,125 Number of shares entitled to vote: 15,062,990 Number of shares with voting rights possessed by shareholders present, represented or having voted by mail: 13,085,075 The Extraordinary General Meeting met on Friday 6 May 2022 at 5 p.m. at the Company's registered office and approv
- Globe Newswire
Pharmagest Interactive: 2021 Net Profit: +25.97% to €41.15m and new name proposal for the Group
Villers-lès-Nancy, 25 March 2022 - 7:00 p.m. (CET) PRESS RELEASE High quality, strong and profitable growth2021 Net Profit: +25.97% to €41.15m Revenue: +12.41% to €193.07m All Divisions contributed to this performance.With the integration of PROKOV EDITIONS in Q4 2021, Pharmagest Group confirms the relevance and effectiveness of its expanded offering with a specific range of software solutions for office-based private practitioners. Solid earnings growth: Operating Profit: +8.95% to €50.26mNet P
